688137 Stock Overview
Researches, develops, produces, and sells raw materials and technical solutions for bio-pharmaceutical enterprises and research institutions in Asia, Europe, the United States, and Oceania. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 1/6 |
My Notes
Capture your thoughts, links and company narrative
Novoprotein Scientific Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥32.12 |
| 52 Week High | CN¥46.60 |
| 52 Week Low | CN¥28.56 |
| Beta | 1.96 |
| 1 Month Change | -8.59% |
| 3 Month Change | -8.70% |
| 1 Year Change | -26.50% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -57.46% |
Recent News & Updates
Recent updates
Shareholder Returns
| 688137 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 2.2% | 3.1% | 3.5% |
| 1Y | -26.5% | -17.3% | 10.9% |
Return vs Industry: 688137 underperformed the CN Biotechs industry which returned -17.3% over the past year.
Return vs Market: 688137 underperformed the CN Market which returned 10.9% over the past year.
Price Volatility
| 688137 volatility | |
|---|---|
| 688137 Average Weekly Movement | 4.3% |
| Biotechs Industry Average Movement | 5.7% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in CN Market | 11.0% |
| 10% least volatile stocks in CN Market | 4.1% |
Stable Share Price: 688137 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688137's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 529 | Huaxing Zhu | www.novoprotein.com.cn |
Novoprotein Scientific Inc. researches, develops, produces, and sells raw materials and technical solutions for bio-pharmaceutical enterprises and research institutions in Asia, Europe, the United States, and Oceania. It offers cytokines, target proteins, mRNA vaccine and drug enzymes, recombinant antibodies, and molecular enzymes and reagents; and gene and cell therapy, molecular research and diagnosis, and SRAS-CoV-2 and SARS-CoV-2 related products, as well as related technical services. The company also provides protein expression and purification, antibody, industrial strain and process development, stable cell line, VLP protein, protein crystallization, protein modification and labeling, MHC I-peptide complex protein preparation, antibody development, mRNA synthesis custom, and vaccine development services.
Novoprotein Scientific Inc. Fundamentals Summary
| 688137 fundamental statistics | |
|---|---|
| Market cap | CN¥2.26b |
| Earnings (TTM) | -CN¥21.29m |
| Revenue (TTM) | CN¥134.56m |
16.7x
P/S Ratio-105.3x
P/E RatioIs 688137 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688137 income statement (TTM) | |
|---|---|
| Revenue | CN¥134.56m |
| Cost of Revenue | CN¥83.88m |
| Gross Profit | CN¥50.69m |
| Other Expenses | CN¥71.98m |
| Earnings | -CN¥21.29m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Apr 29, 2025
| Earnings per share (EPS) | -0.30 |
| Gross Margin | 37.67% |
| Net Profit Margin | -15.82% |
| Debt/Equity Ratio | 0% |
How did 688137 perform over the long term?
See historical performance and comparisonDividends
1.6%
Current Dividend Yield-170%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/20 15:14 |
| End of Day Share Price | 2025/01/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Novoprotein Scientific Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|